Comorbidity in lipoprotein apheresis: Their role in the era of new lipid-lowering therapies.
Charlson comorbidity index
comorbidity
lipoprotein apheresis
polypharmacy
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
revised:
04
09
2023
received:
10
03
2023
accepted:
08
10
2023
medline:
19
10
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
aheadofprint
Résumé
Despite advance in pharmacotherapy of lipid disorders, lipoprotein apheresis (LA) plays a leading role in the management of severe hypercholesterolemia and in atherosclerosis prevention. Aim of this study was to retrospectively evaluate Charlson Comorbidity Index (CCI), presence of major comorbidity, and/or concomitant polypharmacy (definite as 5+ drugs daily) in patients with inherited dyslipidemias on chronic LA. Since 1994, we performed more than 500 LA treatment/year and followed a total of 83 patients (age 56 [47-65] years, male 75%). In subjects with more than 5 years of LA treatment (38 patients, age 54 [45-62] years, male 66%), at the end of the observation time (9 [7-16] years), patients had higher CCI, polypharmacy, anemia, heart failure, peptic ulcer disease, and benign prostatic hyperplasia. Even in the era of new lipid-lowering therapies, the LA treatment established itself as a safe and lifesaving intervention. Patients on chronic LA require a multidisciplinary approach to address their comorbidity and the apheresis unit's medical staff (doctors and nurses) play a pivotal role creating a bridge toward the general practitioner and other specialists for overcoming clinical issues.
Sections du résumé
BACKGROUND
BACKGROUND
Despite advance in pharmacotherapy of lipid disorders, lipoprotein apheresis (LA) plays a leading role in the management of severe hypercholesterolemia and in atherosclerosis prevention.
METHODS
METHODS
Aim of this study was to retrospectively evaluate Charlson Comorbidity Index (CCI), presence of major comorbidity, and/or concomitant polypharmacy (definite as 5+ drugs daily) in patients with inherited dyslipidemias on chronic LA.
RESULTS
RESULTS
Since 1994, we performed more than 500 LA treatment/year and followed a total of 83 patients (age 56 [47-65] years, male 75%). In subjects with more than 5 years of LA treatment (38 patients, age 54 [45-62] years, male 66%), at the end of the observation time (9 [7-16] years), patients had higher CCI, polypharmacy, anemia, heart failure, peptic ulcer disease, and benign prostatic hyperplasia.
DISCUSSION
CONCLUSIONS
Even in the era of new lipid-lowering therapies, the LA treatment established itself as a safe and lifesaving intervention. Patients on chronic LA require a multidisciplinary approach to address their comorbidity and the apheresis unit's medical staff (doctors and nurses) play a pivotal role creating a bridge toward the general practitioner and other specialists for overcoming clinical issues.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Thompson GR. The scientific basis and future of lipoprotein apheresis. Ther Apher Dial. 2022;26:32-36.
Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23:455-468.
Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of Clinimetric properties. Psychother Psychosom. 2022;91:8-35.
Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comorbidity: a review. J Clin Epidemiol. 2001;54:661-674.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
Biagi P, Gussoni G, Iori I, et al. Clinical profile and predictors of in-hospital outcome in patients with heart failure: the FADOI "CONFINE" study. Int J Cardiol. 2011;152:88-94.
Verdiani V, Panigada G, Fortini A, et al. The heart failure in internal medicine in Tuscany: the SMIT study. Ital J Med. 2015;9:349-355.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230.
Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for apheresis: the eighth special issue. J Clin Apher. 2019;34:171-354.
Julius U, Fischer S, Schatz U, Passauer J, Bornstein S. Why an apheresis center should offer more than one lipoprotein apheresis method. Ther Apher Dial. 2013;17:179-184.
https://www.simg.it/Riviste/rivista_simg/2006/05_2006/3.pdf
Carpenter M, Berry H, Pelletier AL. Clinically relevant drug-drug interactions in primary care. Am Fam Physician. 2019;99:558-564.
Volpi E, Giannelli A, Toccafondi G, et al. Medication reconciliation during hospitalization and in hospital-home Interface: an observational retrospective study. J Patient Saf. 2021;17:e143-e148.
McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA. 2002;288:2868-2879.
Bardel A, Wallander MA, Svärdsudd K. Factors associated with adherence to drug therapy: a population-based study. Eur J Clin Pharmacol. 2007;63:307-314.
Cena C, Traina S, Parola B, Bo M, Fagiano R, Siviero C. Prescription of proton pump inhibitors in older adults with complex polytherapy. Eur J Hosp Pharm. 2020;27:341-345.
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137-1146.
Ghionzoli N, Gentile F, Del Franco AM, et al. Current and emerging drug targets in heart failure treatment. Heart Fail Rev. 2022;27:1119-1136.
Manceau H, Ausseil J, Masson D, et al. Neglected comorbidity of chronic heart failure: iron deficiency. Nutrients. 2022;14:3214.
Bramlage CP, Armstrong VW, Zapf A, Bramlage P, Mueller GA, Koziolek MJ. Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients. Ther Apheresis Dial. 2010;14:136-142.
Sbrana F, Dal Pino B, Papa A, Bigazzi F, Panchetti L, Sampietro T. Direct oral anticoagulants in lipoprotein apheresis: handle with care. Intern Emerg Med. 2019;14:1171-1173.
Sbrana F, Ripoli A, Pino BD. Gastroprotection during long-term dual antiplatelet therapy: to give or not to give? J Geriatr Cardiol. 2021;18:973-974.